Norton Drops Teaser For Its Upcoming Motorcycle Ahead Of November 4 Debut
While the teaser video hides many of the details of the bike, it just gives us a glimpse of the sharp and sporty taillight. It must be noted that the brand is planning to introduce a 400cc-450cc and a 650cc machine in the Indian market. However, it is not yet clear whether the bikes will feature a single-cylinder or a dual-cylinder unit.
As of now, all we know is Norton will bring an all-new motorcycle to the country in November based on a new platform, which will open the windows for more motorcycles in the future. Also, a few reports claim that TVS, along with Norton, is working on a 300cc motorcycle that will rival Royal Enfield and Triumph in the Indian market.
Norton India
TVS Motor Company acquired Norton Motorcycles, the iconic British brand, in 2020. This marks a significant milestone in TVS's multi-year strategy to revive and globalise the heritage motorcycle marque. Since acquiring Norton for Rs. 153 crore, TVS has invested over Rs. 1,000 crore into the brand, focusing on product development, R&D, and establishing a new manufacturing facility in Solihull, UK, with a capacity to manufacture around 8,000 motorcycles annually. The company plans to introduce six new models globally by 2027, emphasising "Design, Dynamism, and Detail" as core principles.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
20 minutes ago
- Indian Express
Share price under Rs 200: Multibagger railway stock secured over Rs 1600 crore order last week
Multibagger railway stock order win: A multibagger railway PSU stock secured back-to-back orders last week, according to exchange filings. The total value of these new contracts exceeds Rs 1,600 crore. Can you guess which one? Here's a hint – as of July 20 (NSE data), this railway company has a market capitalisation of Rs 17,563.19 crore. This railway company is none other than IRCON International Limited. IRCON is a navratna company under the Ministry of Railways. Last week (July 14-18), IRCON bagged three new orders. These are as follows: In an exchange filing on July 18, the company said, 'Mumbai Metropolitan Region Development Authority has awarded the work to Ircon International Limited for CA-233, Line-6, Package-2: Design, Manufacture, Supply, Installation, Integration, Testing and Commissioning of Power Supply and Traction, E & M, Lifts & Escalators including 5 Years of Comprehensive Maintenance after 2 Years of Defect Liability Maintenance Period of Line 6 [Swami Samarth Nagar to Vikhroli (EEH)] of Mumbai Metro Rail Project of MMRDA.' The project cost is Rs 642,44,02,451.34. In a separate filing, the railway company said, ' Mumbai Metropolitan Region Development Authority has awarded the work to Ircon International Limited for CA-239, Line-5, Package-2: Design, Manufacture, Supply, Installation, Integration, Testing And Commissioning of 220 kV receiving Substation Including 220 kV, 33kV & 25kV Cabling Work, Complete 25kV Overhead Catenary System along with switching station, 33kV Auxiliary Power Distribution System Including 33/0.415 kV Auxiliary Sub-Station (ASS) And Complete SCADA System, Electrical and Mechanical works, Lift & Escalator Works for part of Main Line, Stations & Kasheli Depot of Mumbai Metro Rail Line 5 Project of MMRDA Including 5 Years of Comprehensive Maintenance after 2 Years of Defect Liability and Maintenance Period.' The project cost is Rs 471,29,72,820. In a filing on Friday, the company said, ' IRCON has been awarded with Letter of Award for the project floated by RVNL (Participated in this bid in JV mode with M/s JPWIPL (i.e., IRCON – 70% & JPIWL – 30%).' Here the total project amount is Rs 755,78,21,993.63 (IRCON Share – Rs 529,04,75,395.53),' the company said. Shares of IRCON closed in red on Friday (July 18). The PSU railway stock settled at Rs 186.74 apiece, down 1.60 per cent on NSE. IRCON International Limited is a component of the BSE 500. According to the BSE analytics (as of July 20), shares of IRCON gave negative returns in the last 1 week and 2 weeks, by 2.20 per cent and 6.27 per cent, respectively. Shares of the PSU railway stock also fell in the last 1 year by 40.25 per cent. However, in the past 2 years, 3 years, and 5 years, shares of the company rose 116.15 per cent, 405.27 per cent, and 307.03 per cent, respectively. This year, IRCON paid a dividend of Rs 1.65 in February. Last year, the PSU railway stock declared total dividends of Rs 3.10. IRCON issued bonuses in the ratio of 1:1 for the equity shareholders.
&w=3840&q=100)
Business Standard
20 minutes ago
- Business Standard
Vedanta rejects baseless allegations, calls Viceroy's claims unfounded
Continuing its triad against mining Moghul Anil Agarwal's Vedanta group, US-based Viceroy Research has alleged that the group's semiconductor unit was a "sham commodities trading operation", designed to avoid classification as an NBFC, a charge the mining conglomerate dismissed as baseless. US short seller Viceroy Research, which last week published a scathing report about Vedanta Group and followed it with similar reports on group companies, in fresh allegations said Vedanta Ltd's subsidiary, Vedanta Semiconductors Pvt Ltd, was part of a scheme to allow the Mumbai-listed firm to remit brand fees to parent Vedanta Resources in April this year, when it faced a severe liquidity crisis. In a statement, Vedanta spokesperson said the group "strongly rejects the baseless allegations made in the report regarding Vedanta Semiconductors Pvt Ltd (VSPL)". "All business activities of VSPL have been transparently disclosed and are in line with statutory norms," it said. Viceroy said, "VSPL is a sham commodities trading operation designed to improperly avoid classification as a Non-Banking Financial Company (NBFC)". "This scheme was devised to facilitate Vedanta Ltd's remittance of brand fees to Vedanta Resources' (VRL) in April 2025, when it faced a severe liquidity crisis," Viceroy said. "VSPL's operational illusion needs 24 months of regulatory silence to fulfil its purpose, repaying its offshore lenders and hiding the near-catastrophe of April 2024. While credit analysts are snoozing through the alarm bells, India's regulators are famously light sleepers." In April 2024, Vedanta Limited (VEDL) faced a severe liquidity crisis. "In response, VEDL reactivated VSPL, not as a semiconductor venture, but as a zero-margin trading entity, whose operations appear to consist entirely of paper-based commodity trading." "VSPL tapped offshore lenders for a short-term, INR-denominated, 10 per cent NCDs secured by VEDL's stake in HZL (equivalent to 1 per cent of outstanding shares). VSPL then began trading commodities (copper, silver, gold) on a zero-margin basis reminiscent of wash trading," Viceroy alleged. VSPL, it said, remitted the loan to VEDL as a 24-month 12 per cent loan, with the spread intended to cover the sham operation's costs. The semiconductor unit, superficially an operating entity, would face reduced scrutiny for loan repayments under FEMA, Companies Act, PMLA and AML frameworks. "VSPL will likely have to continue these sham operations until FY27, when the loans fall due and repayment will have to be routed back through it. If, at any point, the regulators intervene at VSPL, the lender group is likely facing a total wipeout," the US short-seller alleged. Vedanta spokesperson in the statement said, "Loans between VSPL and Vedanta Ltd were executed in full compliance with applicable laws, corporate governance standards, and both Vedanta Ltd and VSPL have consistently reported accurate loan terms, interest rates, and collateral in line with statutory norms," it said, adding that it would encourage stakeholders to only reply on verified disclosures and audited financials. Viceroy, on July 9, said it has taken a short position against the debt of Vedanta Resources, the UK-based parent of Indian miner Vedanta Ltd, and alleged in the report that the British firm is "systematically draining" its Indian unit. Vedanta had dismissed the report as "a malicious combination of selective misinformation and baseless allegations", and that Research issued it without contacting the group. Viceroy, in its latest report, said despite Vedanta's claim that it failed to engage, it is yet to receive a response to the issues flagged since July 9. "For a company so quick to dismiss our findings, one might expect answers to be equally swift. It's been over a week since we formally requested clarification," the short seller added.
Economic Times
20 minutes ago
- Economic Times
Anthem Biosciences IPO: What GMP signals ahead of listing on Monday
Anthem Biosciences is set to debut on the stock exchanges on Monday, July 21. In the unlisted market, its shares are trading at a premium of Rs 165–170, indicating a potential listing gain of around 29% over the IPO price of Rs 570 (upper band). ADVERTISEMENT While the grey market premium (GMP) reflects strong investor interest, it remains a speculative indicator and can change quickly before listing. The Rs 3,395 crore IPO was entirely an offer for sale (OFS) and closed on July 16. It witnessed robust demand, with an overall subscription of 67.42 times. The Qualified Institutional Buyers (QIB) segment was subscribed 192.80 times, Non-Institutional Investors (NII) 44.70 times, and the retail portion 5.98 times. The issue was priced in a band of Rs 540–570 per share, with a minimum lot size of 26 shares. The stock will list on both NSE and BSE. Founded in 2006, Anthem Biosciences operates in a niche segment of the pharma value chain, offering end-to-end drug discovery, development, and manufacturing services. It is among the few Indian CRDMOs with integrated capabilities across both small molecules (chemical-based) and large molecules (biologics).Its differentiated fee-for-service (FFS) model has enabled it to cater to small and mid-sized biotech firms globally, which constitute a large portion of its client base. Since its inception, the company has served over 675 clients and completed more than 8,000 projects. ADVERTISEMENT In FY25, Anthem reported strong financials, with an EBITDA margin of 36.8% and a Return on Net Worth (RoNW) of 20.8%. As of March 2025, the company's net worth stood at Rs 2,410 facilities are cGMP-compliant and approved by global regulatory bodies such as the USFDA, ANVISA, TGA, and PMDA. The company is currently expanding its fermentation and synthesis capacities to meet growing demand for complex biologics and specialty ingredients. ADVERTISEMENT JM Financial is the book-running lead manager of the Anthem Biosciences IPO, while Kfin Technologies is the registrar for the issue. (Disclaimer: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
